vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $340.0M, roughly 1.8× Walker & Dunlop, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -12.9%, a 47.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -0.4%). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
RPRX vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $340.0M |
| Net Profit | $214.2M | $-13.9M |
| Gross Margin | — | — |
| Operating Margin | 62.4% | -17.2% |
| Net Margin | 34.4% | -12.9% |
| Revenue YoY | 4.8% | -0.4% |
| Net Profit YoY | 2.9% | -131.0% |
| EPS (diluted) | $0.49 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $340.0M | ||
| Q3 25 | $609.3M | $337.7M | ||
| Q2 25 | $578.7M | $319.2M | ||
| Q1 25 | $568.2M | $237.4M | ||
| Q4 24 | $593.6M | $341.5M | ||
| Q3 24 | $564.7M | $292.3M | ||
| Q2 24 | $537.3M | $270.7M | ||
| Q1 24 | $568.0M | $228.1M |
| Q4 25 | $214.2M | $-13.9M | ||
| Q3 25 | $288.2M | $33.5M | ||
| Q2 25 | $30.2M | $34.0M | ||
| Q1 25 | $238.3M | $2.8M | ||
| Q4 24 | $208.2M | $44.8M | ||
| Q3 24 | $544.0M | $28.8M | ||
| Q2 24 | $102.0M | $22.7M | ||
| Q1 24 | $4.8M | $11.9M |
| Q4 25 | 62.4% | -17.2% | ||
| Q3 25 | 70.1% | 13.6% | ||
| Q2 25 | 36.3% | 14.5% | ||
| Q1 25 | 94.0% | 2.2% | ||
| Q4 24 | 60.9% | 15.3% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | 50.2% | 10.4% | ||
| Q1 24 | -13.0% | 6.0% |
| Q4 25 | 34.4% | -12.9% | ||
| Q3 25 | 47.3% | 9.9% | ||
| Q2 25 | 5.2% | 10.6% | ||
| Q1 25 | 41.9% | 1.2% | ||
| Q4 24 | 35.1% | 13.1% | ||
| Q3 24 | 96.3% | 9.9% | ||
| Q2 24 | 19.0% | 8.4% | ||
| Q1 24 | 0.8% | 5.2% |
| Q4 25 | $0.49 | $-0.41 | ||
| Q3 25 | $0.67 | $0.98 | ||
| Q2 25 | $0.07 | $0.99 | ||
| Q1 25 | $0.55 | $0.08 | ||
| Q4 24 | $0.46 | $1.32 | ||
| Q3 24 | $1.21 | $0.85 | ||
| Q2 24 | $0.23 | $0.67 | ||
| Q1 24 | $0.01 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $299.3M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $1.7B |
| Total Assets | $19.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $299.3M | ||
| Q3 25 | $938.9M | $274.8M | ||
| Q2 25 | $631.9M | $233.7M | ||
| Q1 25 | $1.1B | $181.0M | ||
| Q4 24 | $929.0M | $279.3M | ||
| Q3 24 | $950.1M | $179.8M | ||
| Q2 24 | $1.8B | $208.1M | ||
| Q1 24 | $843.0M | $216.5M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $1.7B | ||
| Q3 25 | $9.6B | $1.8B | ||
| Q2 25 | $9.5B | $1.8B | ||
| Q1 25 | $9.8B | $1.7B | ||
| Q4 24 | $10.3B | $1.7B | ||
| Q3 24 | $10.3B | $1.7B | ||
| Q2 24 | $9.8B | $1.7B | ||
| Q1 24 | $9.9B | $1.7B |
| Q4 25 | $19.6B | $5.1B | ||
| Q3 25 | $19.3B | $5.8B | ||
| Q2 25 | $18.3B | $4.7B | ||
| Q1 25 | $17.6B | $4.5B | ||
| Q4 24 | $18.2B | $4.4B | ||
| Q3 24 | $18.0B | $4.6B | ||
| Q2 24 | $17.7B | $4.2B | ||
| Q1 24 | $16.1B | $3.8B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $-664.3M |
| Free Cash FlowOCF − Capex | — | $-680.1M |
| FCF MarginFCF / Revenue | — | -200.0% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $-664.3M | ||
| Q3 25 | $702.6M | $-948.1M | ||
| Q2 25 | $364.0M | $-238.5M | ||
| Q1 25 | $596.1M | $-281.1M | ||
| Q4 24 | $742.5M | $129.4M | ||
| Q3 24 | $703.6M | $-202.0M | ||
| Q2 24 | $658.2M | $-237.8M | ||
| Q1 24 | $664.6M | $38.4M |
| Q4 25 | — | $-680.1M | ||
| Q3 25 | — | $-950.4M | ||
| Q2 25 | — | $-241.0M | ||
| Q1 25 | — | $-284.7M | ||
| Q4 24 | — | $116.4M | ||
| Q3 24 | — | $-204.0M | ||
| Q2 24 | — | $-241.7M | ||
| Q1 24 | — | $35.2M |
| Q4 25 | — | -200.0% | ||
| Q3 25 | — | -281.5% | ||
| Q2 25 | — | -75.5% | ||
| Q1 25 | — | -120.0% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | -69.8% | ||
| Q2 24 | — | -89.3% | ||
| Q1 24 | — | 15.4% |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | -28.34× | ||
| Q2 25 | 12.06× | -7.02× | ||
| Q1 25 | 2.50× | -102.07× | ||
| Q4 24 | 3.57× | 2.89× | ||
| Q3 24 | 1.29× | -7.01× | ||
| Q2 24 | 6.45× | -10.49× | ||
| Q1 24 | 139.10× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
WD
Segment breakdown not available.
